Merck KGaA’s allergy business, Allergopharma, has opened a new EUR 42 million ($45 million) biopharmaceutical production facility in Reinbek, Germany, near Hamburg, Germany.

The new biopharmaceutical production facility covers 6,000 square meters and houses a glass cleanroom, in which the company will manufacture products for treating allergies. The new building’s technological operations are modernized, and the facility is equipped with the potential for extension to accommodate further filling lines.

Allergopharma, the allergy business of the healthcare business sector of Merck KGaA, focuses on allergen immunotherapy of Type I allergies, such as hay fever or allergic asthma.

Source: Merck KGaA